Articles

UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (44921) 44921
Newspaper Article (2152) 2152
Patent (1317) 1317
Newsletter (869) 869
Book Chapter (534) 534
Magazine Article (72) 72
Book / eBook (31) 31
Dissertation (30) 30
Transcript (17) 17
Trade Publication Article (16) 16
Publication (15) 15
Conference Proceeding (8) 8
Book Review (7) 7
Web Resource (7) 7
Reference (3) 3
Government Document (2) 2
Report (2) 2
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
science & technology (35817) 35817
life sciences & biomedicine (32365) 32365
humans (28979) 28979
male (17363) 17363
peptides (15919) 15919
female (15682) 15682
animals (14660) 14660
middle aged (9937) 9937
biological and medical sciences (8654) 8654
aged (7578) 7578
medical sciences (7469) 7469
adult (7457) 7457
proteins (5624) 5624
mice (5589) 5589
lipids (5452) 5452
research (5258) 5258
analysis (4671) 4671
cardiovascular system & cardiology (4496) 4496
pharmacology & pharmacy (4352) 4352
treatment outcome (4232) 4232
diabetes (4090) 4090
abridged index medicus (4032) 4032
risk factors (3993) 3993
health aspects (3974) 3974
cardiac & cardiovascular systems (3902) 3902
rats (3763) 3763
care and treatment (3727) 3727
endocrinology & metabolism (3638) 3638
medicine (3613) 3613
biochemistry & molecular biology (3299) 3299
research article (3279) 3279
science & technology - other topics (3187) 3187
chemistry (3180) 3180
biomarkers - blood (3082) 3082
neurosciences & neurology (2999) 2999
clinical trials (2991) 2991
heart failure (2960) 2960
physiological aspects (2940) 2940
immunology (2935) 2935
studies (2892) 2892
rodents (2766) 2766
neurosciences (2754) 2754
multidisciplinary sciences (2732) 2732
time factors (2730) 2730
patients (2700) 2700
drug therapy (2579) 2579
cancer (2547) 2547
inflammation (2521) 2521
oncology (2519) 2519
gene expression (2486) 2486
pharmacology. drug treatments (2447) 2447
disease models, animal (2393) 2393
natriuretic peptide, brain - blood (2376) 2376
medicine, research & experimental (2369) 2369
research & experimental medicine (2365) 2365
medical research (2363) 2363
natriuretic peptides (2363) 2363
medicine & public health (2336) 2336
cell biology (2332) 2332
insulin (2325) 2325
mortality (2255) 2255
science (2244) 2244
fundamental and applied biological sciences. psychology (2226) 2226
enzymes (2153) 2153
glucose (2141) 2141
prospective studies (2120) 2120
aged, 80 and over (2112) 2112
cardiovascular disease (2094) 2094
prognosis (2054) 2054
metabolism (2037) 2037
type 2 diabetes (2000) 2000
review (1994) 1994
heart (1985) 1985
peptide fragments - blood (1962) 1962
internal medicine (1955) 1955
diabetes mellitus, type 2 - drug therapy (1946) 1946
biomarkers (1941) 1941
biochemistry (1931) 1931
dose-response relationship, drug (1918) 1918
adolescent (1916) 1916
double-blind method (1850) 1850
physiology (1848) 1848
general & internal medicine (1817) 1817
obesity (1803) 1803
mice, inbred c57bl (1798) 1798
peptides - therapeutic use (1782) 1782
surgery (1766) 1766
organic chemistry (1748) 1748
cardiovascular diseases (1720) 1720
physical sciences (1718) 1718
cholesterol (1707) 1707
apoptosis (1704) 1704
tumors (1688) 1688
cardiology (1682) 1682
neurology (1660) 1660
young adult (1642) 1642
microbiology (1603) 1603
cytokines (1601) 1601
diabetes mellitus (1601) 1601
rats, sprague-dawley (1571) 1571
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (14) 14
Collection Dvlpm't (Acquisitions) - Vendor file (6) 6
Online Resources - Online (6) 6
Collection Dvlpm't (Acquisitions) - Closed Orders (1) 1
Dentistry (Harry R Abbott) - Stacks (1) 1
Sunnybrook Health Sciences Centre - Sunnybrook Stacks (1) 1
UTL at Downsview - May be requested (1) 1
UofT at Scarborough - Stacks (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (49120) 49120
French (452) 452
German (387) 387
Japanese (332) 332
Chinese (230) 230
Russian (193) 193
Spanish (147) 147
Portuguese (110) 110
Korean (53) 53
Polish (45) 45
Italian (39) 39
Norwegian (34) 34
Danish (29) 29
Hungarian (26) 26
Swedish (18) 18
Czech (13) 13
Dutch (13) 13
Finnish (12) 12
Turkish (11) 11
Croatian (7) 7
Hebrew (7) 7
Greek (4) 4
Lithuanian (4) 4
Romanian (4) 4
Slovenian (4) 4
Bulgarian (3) 3
Serbian (3) 3
Slovak (2) 2
Ukrainian (2) 2
Bosnian (1) 1
Persian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Parenteral anticoagulants - Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines
by Garcia, David A and Baglin, Trevor P and Weitz, Jeffrey I and Samama, Meyer Michel
Chest, ISSN 0012-3692, 2012, Volume 141, Issue 2, pp. e24S - e43S
Respiratory System | Life Sciences & Biomedicine | Critical Care Medicine | General & Internal Medicine | Science & Technology | Heparitin Sulfate - adverse effects | United States | Humans | Thrombin - antagonists & inhibitors | Heparin - administration & dosage | Heparin, Low-Molecular-Weight - adverse effects | Recombinant Proteins - adverse effects | Heparin - adverse effects | Hirudins - administration & dosage | Dose-Response Relationship, Drug | Pipecolic Acids - administration & dosage | Chondroitin Sulfates - adverse effects | Societies, Medical | Pipecolic Acids - adverse effects | Heparitin Sulfate - administration & dosage | Polysaccharides - administration & dosage | Thrombosis - blood | Thrombosis - prevention & control | Dermatan Sulfate - administration & dosage | Dermatan Sulfate - adverse effects | Peptide Fragments - administration & dosage | Polysaccharides - adverse effects | Evidence-Based Medicine | Recombinant Proteins - administration & dosage | Antithrombins - agonists | Chondroitin Sulfates - administration & dosage | Hirudins - adverse effects | Fibrinolytic Agents - administration & dosage | Peptide Fragments - adverse effects | Thrombosis - drug therapy | Heparin, Low-Molecular-Weight - administration & dosage | Infusions, Intravenous | Practice Guidelines as Topic | Index Medicus | Abridged Index Medicus | Antithrombotic Therapy and Prevention of Thrombosis, 9th Ed | American College of Chest Physician Evidence-Based Clinical Practice Guidelines Online Only
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Development of surface modified biodegradable polymeric nanoparticles to deliver GSE24.2 peptide to cells: A promising approach for the treatment of defective telomerase disorders
by Egusquiaguirre, Susana P and Manguán-García, Cristina and Pintado-Berninches, Laura and Iarriccio, Laura and Carbajo, Daniel and Albericio, Fernando and Royo, Miriam and Pedraz, José Luís and Hernández, Rosa M and Perona, Rosario and Igartua, Manuela
European journal of pharmaceutics and biopharmaceutics, ISSN 0939-6411, 04/2015, Volume 91, pp. 91 - 102
Dyskeratosis congenita | GSE24.2 peptide | Cell-penetrating peptides | Biodegradable nanoparticles | Polycations | Telomerase reactivation | Dyskeratosis congenital | Life Sciences & Biomedicine | Pharmacology & Pharmacy | Science & Technology | Recombinant Proteins - therapeutic use | Dyskeratosis Congenita - drug therapy | Nanoparticles - chemistry | Biocompatible Materials - chemistry | Humans | Enzyme Reactivators - administration & dosage | Polyethylene Glycols - chemistry | Telomerase - deficiency | Biological Transport | Drug Compounding | Telomerase - metabolism | Peptide Fragments - genetics | Cell Survival - drug effects | Lactic Acid - chemistry | Polyamines - chemistry | Enzyme Reactivators - chemistry | Recombinant Proteins - chemistry | Nuclear Proteins - chemistry | Peptide Fragments - chemistry | Delayed-Action Preparations - adverse effects | Telomerase - chemistry | Delayed-Action Preparations - therapeutic use | Drug Liberation | Lactic Acid - adverse effects | Polyglactin 910 - adverse effects | Mice | Peptide Fragments - adverse effects | Biocompatible Materials - adverse effects | Drug Delivery Systems - adverse effects | Polyamines - adverse effects | Polyglycolic Acid - adverse effects | Polyethylene Glycols - adverse effects | Delayed-Action Preparations - chemistry | Nanoparticles - adverse effects | Recombinant Proteins - adverse effects | Cell Cycle Proteins - administration & dosage | Delayed-Action Preparations - administration & dosage | Cell Cycle Proteins - chemistry | Nuclear Proteins - administration & dosage | Cell-Penetrating Peptides - adverse effects | Chemical Phenomena | Cell Cycle Proteins - genetics | Polyglactin 910 - chemistry | Protein Stability | Nuclear Proteins - genetics | Cell-Penetrating Peptides - chemistry | Cell Line | Cell Cycle Proteins - adverse effects | Drug Stability | Peptide Fragments - administration & dosage | Cells, Cultured | Nuclear Proteins - adverse effects | Recombinant Proteins - administration & dosage | Enzyme Reactivators - therapeutic use | Animals | Enzyme Reactivators - adverse effects | Polyglycolic Acid - chemistry | Peptides | Telomerase | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Immunotherapy for Alzheimer disease-the challenge of adverse effects
by Liu, Yu-Hui and Giunta, Brian and Zhou, Hua-Dong and Tan, Jun and Wang, Yan-Jiang
Nature reviews. Neurology, ISSN 1759-4758, 08/2012, Volume 8, Issue 8, pp. 465 - 469
Antibodies - metabolism | Humans | Alzheimer Disease - therapy | Amyloid beta-Peptides - immunology | Antibodies - adverse effects | Clinical Trials as Topic | Alzheimer Disease - immunology | Immunotherapy - adverse effects | Care and treatment | Immunotherapy | Amyloid beta-protein | Physiological aspects | Research | Alzheimer's disease | Health aspects | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Mechanisms underlying adverse effects of HDL on eNOS-activating pathways in patients with coronary artery disease
by Besler, Christian and Heinrich, Kathrin and Rohrer, Lucia and Doerries, Carola and Riwanto, Meliana and Shih, Diana M and Chroni, Angeliki and Yonekawa, Keiko and Stein, Sokrates and Schaefer, Nicola and Mueller, Maja and Akhmedov, Alexander and Daniil, Georgios and Manes, Costantina and Templin, Christian and Wyss, Christophe and Maier, Willibald and Tanner, Felix C and Matter, Christian M and Corti, Roberto and Furlong, Clement and Lusis, Aldons J and Von Eckardstein, Arnold and Fogelman, Alan M and Lüscher, Thomas F and Landmesser, Ulf
The Journal of clinical investigation, ISSN 0021-9738, 07/2011, Volume 121, Issue 7, pp. 2693 - 2708
Life Sciences & Biomedicine | Medicine, Research & Experimental | Science & Technology | Research & Experimental Medicine | Tumor Necrosis Factor-alpha - metabolism | Nitric Oxide - biosynthesis | Coronary Artery Disease - metabolism | Humans | Middle Aged | Lipoproteins, HDL - metabolism | Male | NF-kappa B - metabolism | Aryldialkylphosphatase - metabolism | Animals | Coronary Artery Disease - physiopathology | Endothelium, Vascular - metabolism | Adult | Female | Aged | Mice | Nitric Oxide Synthase Type III - metabolism | Proto-Oncogene Proteins c-akt - metabolism | Vascular Cell Adhesion Molecule-1 - metabolism | Prevention | Enzymes | Care and treatment | High density lipoproteins | Physiological aspects | Research | Coronary heart disease | Endothelium | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Efficacy and safety of dulaglutide added onto pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1)
by Wysham, Carol and Blevins, Thomas and Arakaki, Richard and Colon, Gildred and Garcia, Pedro and Atisso, Charles and Kuhstoss, Debra and Lakshmanan, Mark
Diabetes care, ISSN 0149-5992, 2014, Volume 37, Issue 8, pp. 2159 - 2167
Diabetes. Impaired glucose tolerance | Biological and medical sciences | Endocrinopathies | Etiopathogenesis. Screening. Investigations. Target tissue resistance | Metabolic diseases | Medical sciences | Endocrine pancreas. Apud cells (diseases) | Recombinant Fusion Proteins - adverse effects | Glucagon-Like Peptides - administration & dosage | Humans | Middle Aged | Male | Immunoglobulin Fc Fragments - administration & dosage | Thiazolidinediones - administration & dosage | Metformin - adverse effects | Peptides - administration & dosage | Hypoglycemic Agents - administration & dosage | Venoms - administration & dosage | Female | Metformin - administration & dosage | Drug Therapy, Combination | Glucagon-Like Peptides - analogs & derivatives | Immunoglobulin Fc Fragments - adverse effects | Recombinant Fusion Proteins - administration & dosage | Drug Administration Schedule | Venoms - adverse effects | Hypoglycemia - drug therapy | Thiazolidinediones - adverse effects | Blood Glucose - drug effects | Glucagon-Like Peptides - adverse effects | Aged | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Peptides - adverse effects | Type 2 diabetes | Care and treatment | Safety and security measures | Dosage and administration | Metformin | Comparative analysis | Exenatide | Clinical trials | Hemoglobin | Diabetes | Product safety | Drug dosages | Placebo effect | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Bivalirudin vs Heparin With or Without Tirofiban During Primary Percutaneous Coronary Intervention in Acute Myocardial Infarction: The BRIGHT Randomized Clinical Trial
by Han, Yaling and Guo, Jincheng and Zheng, Yang and Zang, Hongyun and Su, Xi and Wang, Yu and Chen, Shaoliang and Jiang, Tiemin and Yang, Ping and Chen, Jiyan and Jiang, Dongju and Jing, Quanmin and Liang, Zhenyang and Liu, Haiwei and Zhao, Xin and Li, Jing and Li, Yi and Xu, Bo and Stone, Gregg W and BRIGHT Investigators
JAMA : the journal of the American Medical Association, ISSN 0098-7484, 03/2015, Volume 313, Issue 13, pp. 1336 - 1346
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Recombinant Proteins - therapeutic use | Antithrombins - therapeutic use | Humans | Middle Aged | Heparin - therapeutic use | Male | Recombinant Proteins - adverse effects | Heparin - adverse effects | Tyrosine - analogs & derivatives | Fibrinolytic Agents - adverse effects | Myocardial Infarction - therapy | Myocardial Infarction - drug therapy | Tyrosine - therapeutic use | Antithrombins - adverse effects | Fibrinolytic Agents - therapeutic use | Hirudins - adverse effects | Female | Tyrosine - adverse effects | Aged | Peptide Fragments - adverse effects | Peptide Fragments - therapeutic use | Hemorrhage - chemically induced | Drug Therapy, Combination | Percutaneous Coronary Intervention | Care and treatment | Usage | Angiography | Patient outcomes | Clinical trials | Bivalirudin | Dosage and administration | Heart attack | Medical research | Side effects | Inhibitor drugs | Heart attacks | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Risk of incident diabetes among patients treated with statins: population based study
by Carter, Aleesa A and Gomes, Tara and Camacho, Ximena and Juurlink, David N and Shah, Baiju R and Mamdani, Muhammad M
BMJ : British Medical Journal, ISSN 0959-8138, 5/2013, Volume 346, Issue 7911, pp. 14 - 14
RESEARCH | Secondary prevention | Depopulation | Population growth | Diabetes | Older adults | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage | Simvastatin - adverse effects | Cardiovascular Diseases - prevention & control | Humans | Male | Fluorobenzenes - administration & dosage | Heptanoic Acids - adverse effects | Diabetes Mellitus, Type 2 - epidemiology | Incidence | Dose-Response Relationship, Drug | Pyrroles - administration & dosage | Cardiovascular Diseases - epidemiology | Heptanoic Acids - administration & dosage | Pravastatin - adverse effects | Pyrroles - adverse effects | Diabetes Mellitus, Type 2 - etiology | Female | Retrospective Studies | Odds Ratio | Dyslipidemias - drug therapy | Pyrimidines - administration & dosage | Simvastatin - administration & dosage | Proportional Hazards Models | Rosuvastatin Calcium | Treatment Outcome | Atorvastatin Calcium | Dyslipidemias - epidemiology | Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects | Pravastatin - administration & dosage | Ontario - epidemiology | Pyrimidines - adverse effects | Sulfonamides - adverse effects | Aged | Fluorobenzenes - adverse effects | Diabetes Mellitus, Type 2 - chemically induced | Population Surveillance | Sulfonamides - administration & dosage | Cohort Studies | Inhibitor drugs | Risk assessment | Statins | Clinical outcomes | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Pancreatitis, Pancreatic, and Thyroid Cancer With Glucagon-Like Peptide-1–Based Therapies
by Elashoff, Michael and Matveyenko, Aleksey V and Gier, Belinda and Elashoff, Robert and Butler, Peter C
Gastroenterology (New York, N.Y. 1943), ISSN 0016-5085, 2011, Volume 141, Issue 1, pp. 150 - 156
Gastroenterology and Hepatology | Side Effect | Tumor | Pancreas | Toxicity | Gastroenterology & Hepatology | Life Sciences & Biomedicine | Science & Technology | Receptors, Glucagon - agonists | Triazoles - adverse effects | United States - epidemiology | Pancreatic Neoplasms - epidemiology | Risk Assessment | Adverse Drug Reaction Reporting Systems | Dipeptidyl-Peptidase IV Inhibitors - adverse effects | Pancreatitis - epidemiology | Venoms - adverse effects | Humans | Risk Factors | Thyroid Neoplasms - epidemiology | Pancreatitis - chemically induced | Diabetes Mellitus, Type 2 - epidemiology | Thyroid Neoplasms - chemically induced | Glucagon-Like Peptide-1 Receptor | Pyrazines - adverse effects | Pancreatic Neoplasms - chemically induced | Sitagliptin Phosphate | Diabetes Mellitus, Type 2 - drug therapy | Odds Ratio | Hypoglycemic Agents - adverse effects | Peptides - adverse effects | United States Food and Drug Administration | Type 2 diabetes | Care and treatment | Thyroid cancer | Peptides | Pancreatitis | Cancer | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Encapsulation of Exenatide in Poly-(d,l-Lactide-Co-Glycolide) Microspheres Produced an Investigational Long-Acting Once-Weekly Formulation for Type 2 Diabetes
by DeYoung, Mary Beth and MacConell, Leigh and Sarin, Viren and Trautmann, Michael and Herbert, Paul
Diabetes t